Department of Obstetrics and Gynecology, Radboud University Medical Centre, Nijmegen, The Netherlands; Department of Obstetrics and Gynecology, Maastricht University Medical Centre, Maastricht, The Netherlands; GROW - School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.
Gynecol Oncol. 2013 Dec;131(3):561-6. doi: 10.1016/j.ygyno.2013.09.016. Epub 2013 Sep 21.
Evidence of randomized comparative clinical trials on surgery in recurrent platinum-sensitive ovarian cancer is non-existing. Three randomized phase 3 trials are ongoing. The aim of this study is to evaluate the current opinion of Dutch gynecologists and medical oncologists awaiting the results of these three trials.
A 16-item questionnaire was sent to all gynecologists (N=124) and medical oncologists (N=195) with special interest in gynecologic oncology in the Netherlands. The data were collected and analyzed using descriptive statistics.
In total, 80 (65.0%) gynecologists and 67 (34.0%) medical oncologists responded. Among the respondents, 11.3% and 26.9% were not convinced of the benefit of secondary cytoreductive surgery, respectively. For most gynecologists and medical oncologists completeness of primary surgery (74.6% and 75.5%, respectively) and performance status (100% and 98%, respectively) were important factors when considering surgery. For only about 17.5% of all respondents diagnostic laparoscopy before surgery is a prerequisite. Most respondents (81.7% and 87.8%, respectively) would use platinum-based chemotherapy with paclitaxel as their agents of choice after surgery. In general medical oncologists settle for a smaller gain in both progression free as well as overall survival than gynecologists.
Although most gynecologists and medical oncologists are already convinced of the usefulness of secondary cytoreductive surgery in certain patients, a better understanding of the real advantages and disadvantages and patient's selection criteria for secondary cytoreductive surgery will be achieved after the completion of three ongoing randomized controlled trials (DESKTOP III, GOG 213 and the SOCceR).
在复发性铂类敏感卵巢癌的手术方面，尚无随机对照临床试验的证据。目前正在进行三项随机 III 期临床试验。本研究旨在评估荷兰妇科肿瘤学家和肿瘤内科医生对这三项试验结果的期待。
向荷兰所有妇科肿瘤学家（n=124）和对妇科肿瘤学有特殊兴趣的肿瘤内科医生（n=195）发送了一份包含 16 个问题的问卷。使用描述性统计方法收集和分析数据。
共有 80 名妇科肿瘤学家（65.0%）和 67 名肿瘤内科医生（34.0%）做出了回应。在回答者中，分别有 11.3%和 26.9%对二次细胞减灭术的益处表示怀疑。对于大多数妇科肿瘤学家和肿瘤内科医生来说，初次手术的完整性（分别为 74.6%和 75.5%）和表现状态（100%和 98%）是考虑手术的重要因素。对于只有约 17.5%的所有受访者，手术前的诊断性腹腔镜检查是一个前提条件。大多数受访者（分别为 81.7%和 87.8%）在手术后会选择铂类联合紫杉醇的化疗方案。一般来说，肿瘤内科医生在无进展生存期和总生存期方面的获益都比妇科肿瘤学家小。
尽管大多数妇科肿瘤学家和肿瘤内科医生已经对二次细胞减灭术在某些患者中的有用性表示认可，但在三项正在进行的随机对照试验（DESKTOP III、GOG 213 和 SOCceR）完成后，将更好地了解二次细胞减灭术的真正优势和劣势以及患者的选择标准。
